Myelo 001

Drug Profile

Myelo 001

Alternative Names: Imidazolyl ethanamide pentandioic acid; Ingavirin; Myelo001; Vitaglutam

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Valenta Pharmaceuticals
  • Developer Myelo Therapeutics; Valenta Pharmaceuticals
  • Class Antivirals; Imidazoles; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Granulocyte stimulants; Haematopoiesis stimulants; Neutrophil stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neutropenia; Viral infections

Most Recent Events

  • 08 Aug 2017 Chemical structure information added
  • 01 May 2016 Valenta Pharmaceuticals completes the phase III ACCORD trial in Viral infections (In children) in Russia (NCT02644018)
  • 09 Dec 2015 Phase-II clinical trials in Neutropenia (Chemotherapy-induced) in Germany (PO) (EudraCT2015-003610-25)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top